Nivolumab

Monoclonal antibody

Also known as ONO-4538

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Metastatic Colorectal Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Colorectal Cancer, Advanced Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (6)
US
  • Opdivo, in combination with doxorubicin, vinblastine, and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL)Outside this platform's coverageFDA label
  • Malignant Pleural Mesothelioma OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Outside this platform's coverageFDA label
  • Classical Hodgkin lymphoma (cHL): adult and pediatric (12 years and older) patients with previously untreated Stage III or IV cHL in combination with doxorubicin, vinblastine, and dacarbazine; adults with cHL that has relapsed or progressed after autologous HSCT and brentuximab vedotin, or after 3 or more lines of systemic therapy that includes autologous HSCT
    FDA label
  • Adjuvant treatment of adults with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT)Outside this platform's coverageFDA label
Product first approved 2015
EU
  • Opdivo (nivolumab): initial indication advanced melanoma; later extended to NSCLC and other cancers
Product first approved 2015EMA
JP
  • Unresectable melanoma (first approval worldwide of a PD-1 checkpoint inhibitor; Ono Pharmaceutical)
Product first approved 2014pharmatimes.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (126)
Advanced Metastatic Colorectal Cancer
NCT05328908 · Bristol-Myers Squibb
2022-04-28 – 2025-07-14 · Colorectal Neoplasms
What this study did
Gastric Cancer
NCT07431281 · AstraZeneca
2026-02-03 – 2031-10-27 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
What this study did
NCT05677490 · Alliance for Clinical Trials in Oncology
2023-01-31 – 2028-11-08 · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03006705 · Ono Pharmaceutical Co., Ltd.
2017-01-31 – 2023-03-31 · Gastric Cancer
What this study did
NCT02267343 · Ono Pharmaceutical Co., Ltd.
2014-10 – 2021-01 · Gastric Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT03576417 · Groupe Oncologie Radiotherapie Tete et Cou
2018-10-10 – 2027-09 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT03700905 · Universitätsklinikum Hamburg-Eppendorf
2018-08-21 – 2024-05 · Head and Neck Cancer
What this study did
NCT05802290 · Gruppo Oncologico del Nord-Ovest
2017-11-27 – 2020-03-26 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT03349710 · Bristol-Myers Squibb
2017-12-15 – 2019-10-14 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT03342352 · Incyte Corporation
2017-12-15 – 2018-04-20 · Head and Neck Cancer
What this study did
Hepatocellular Carcinoma
NCT03383458 · Bristol-Myers Squibb
2018-04-18 – 2031-05-27 · Hepatocellular Carcinoma, Liver Cancer
What this study did
NCT07620574 · Exelixis
2026-07-30 – 2030-05-31 · Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer
What this study did
NCT02576509 · Bristol-Myers Squibb
2015-12-07 – 2024-02-07 · Hepatocellular Carcinoma
What this study did
Melanoma
NCT06488482 · Uppsala University
2024-12-19 – 2033-09 · High-risk Melanoma
What this study did
NCT06794775 · Hildur Helgadottir
2025-07-10 – 2032-04-15 · Malignant Melanoma Stage III
What this study did
NCT06264180 · Replimune, Inc.
2024-07-11 – 2031-03-31 · Advanced Melanoma
What this study did
NCT07221734 · mAbxience Research S.L.
2025-12-29 – 2029-02 · Advanced (Unresectable or Metastatic) Melanoma
What this study did
NCT04949113 · The Netherlands Cancer Institute
2021-07-08 – 2028-12-19 · Malignant Melanoma Stage III
What this study did
NCT06054555 · Amgen
2023-11-02 – 2028-01-25 · Melanoma
What this study did
NCT04309409 · University Hospital, Essen
2020-07-01 – 2028-01 · Malignant Melanoma Stage II
What this study did
NCT05625399 · Bristol-Myers Squibb
2023-03-06 – 2027-11-18 · Melanoma
What this study did
NCT06112314 · Immunocore Ltd
2024-06-05 – 2027-10-16 · Advanced Melanoma
What this study did
NCT06640530 · Biocad
2024-03-21 – 2027-03 · Advanced Melanoma, Melanoma (Skin)
What this study did
NCT02224781 · National Cancer Institute (NCI)
2015-09-08 – 2026-12-19 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
What this study did
NCT04674683 · HUYABIO International, LLC.
2021-08-12 – 2026-12 · Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
What this study did
NCT05907122 · Amgen
2023-07-26 – 2025-10-31 · Melanoma
What this study did
NCT05002569 · Bristol-Myers Squibb
2021-10-19 – 2025-04-02 · Melanoma
What this study did
NCT03635983 · Bristol-Myers Squibb
2018-09-21 – 2024-03-19 · Melanoma
What this study did
NCT05297565 · Bristol-Myers Squibb
2022-08-02 – 2024-02-08 · Melanoma
What this study did
NCT04410445 · Nektar Therapeutics
2020-07-27 – 2022-09-22 · Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
What this study did
NCT03329846 · Bristol-Myers Squibb
2017-11-30 – 2020-07-02 · Melanoma, Skin Cancer
What this study did
NCT02599402 · Bristol-Myers Squibb
2015-12-20 – 2020-02-10 · Melanoma
What this study did
NCT02460068 · Italian Network for Tumor Biotherapy Foundation
2012-12 – 2020-01 · Brain Metastases
What this study did
NCT02905266 · Bristol-Myers Squibb
2016-10-27 – 2019-10-25 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04564157 · Fundación GECP
2021-01-13 – 2031-04-01 · Non-Small Cell Lung Cancer, Adjuvant Chemotherapy
What this study did
Phase 2/3 (21)
Colorectal Cancer
Esophageal Squamous Cell Carcinoma
NCT05213312 · Shanghai Zhongshan Hospital
2022-06-01 – 2024-03-01 · Esophageal Squamous Cell Carcinoma
What this study did
Gastric Cancer
NCT06203600 · National Cancer Institute (NCI)
2024-06-24 – 2027-10-31 · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT02746796 · Ono Pharmaceutical Co., Ltd.
2016-03 – 2022-11-17 · Gastric Cancer
What this study did
Hepatocellular Carcinoma
NCT04268888 · The Clatterbridge Cancer Centre NHS Foundation Trust
2019-05-08 – 2026-06-30 · Hepatocellular Carcinoma
What this study did
NCT04044651 · Shi Ming
2019-10-30 – 2022-09-30 · Hepatocellular Carcinoma
What this study did
Melanoma
NCT02339571 · National Cancer Institute (NCI)
2015-11-23 – 2033-06-30 · Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
NCT03470922 · Bristol-Myers Squibb
2018-04-11 – 2030-12-15 · Melanoma
What this study did
NCT04695977 · Regeneron Pharmaceuticals
2021-02-24 – 2024-07-22 · Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
What this study did
NCT04901988 · The Christie NHS Foundation Trust
2021-11-08 – 2023-01-30 · Melanoma (Skin), Melanoma, Stage II
What this study did
Non-Small Cell Lung Cancer
NCT04929041 · National Cancer Institute (NCI)
2022-10-07 – 2030-12-12 · Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
Urothelial Carcinoma
NCT05987241 · National Cancer Institute (NCI)
2024-02-02 – 2030-09-02 · Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
What this study did
Other / comorbidity
NCT07572123 · National Cancer Institute (NCI)
2026-12-04 – 2029-03-31 · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
What this study did
NCT03604991 · National Cancer Institute (NCI)
2019-05-03 – 2027-03-31 · Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03952585 · National Cancer Institute (NCI)
2019-10-09 – 2026-12-11 · Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
What this study did
NCT04396860 · National Cancer Institute (NCI)
2020-09-01 – 2025-12-23 · Gliosarcoma, MGMT-Unmethylated Glioblastoma
What this study did
NCT04887870 · Mirati Therapeutics Inc.
2021-06-29 – 2025-09-25 · Advanced or Metastatic Solid Malignancies
What this study did
NCT03366272 · Universität des Saarlandes
2017-12-05 – 2025-01-15 · Lymphoma, Non-Hodgkin
What this study did
NCT03879122 · Spanish Oncology Genito-Urinary Group
2019-02-11 – 2024-12-31 · Metastatic Hormone-sensitive Prostate Cancer
What this study did
NCT03092674 · National Cancer Institute (NCI)
2018-02-02 – 2024-06-26 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
What this study did
Phase 2 (734)
Advanced Metastatic Colorectal Cancer
NCT06245356 · UNICANCER
2025-03-21 – 2028-10-21 · Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
What this study did
NCT04729322 · M.D. Anderson Cancer Center
2021-02-22 – 2027-12-31 · Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
What this study did
NCT05310643 · GERCOR - Multidisciplinary Oncology Cooperative Group
2022-05-05 – 2027-09 · Metastatic Colorectal Cancer
What this study did
NCT03350126 · GERCOR - Multidisciplinary Oncology Cooperative Group
2017-12-04 – 2025-12 · Metastatic Cancer Colorectal
What this study did
NCT03867799 · Royal Marsden NHS Foundation Trust
2019-03-27 – 2024-09 · Metastatic Colorectal Cancer
What this study did
NCT03547999 · Patrick Boland
2018-06-26 – 2024-03-13 · Metastatic Colorectal Cancer
What this study did
NCT04166383 · National Cancer Institute (NCI)
2020-08-09 – 2022-12-31 · Metastatic Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Tumors
What this study did
NCT03785210 · National Cancer Institute (NCI)
2019-06-05 – 2022-12-31 · Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, Liver Metastasis
What this study did
NCT03832621 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2019-03-25 – 2021-09-30 · Metastatic Colorectal Cancer
What this study did
NCT04430985 · Dorte Nielsen
2020-09-30 – 2021-09-06 · Metastatic Colorectal Cancer
What this study did
NCT02860546 · Taiho Oncology, Inc.
2016-08-29 – 2017-09-07 · Refractory Metastatic Colorectal Cancer
What this study did
Colorectal Cancer
NCT07011550 · M.D. Anderson Cancer Center
2025-08-15 – 2030-07-01 · Microsatellite-stable Colorectal Cancer, Standard of Care, Nivolumab, Bevacizumab
What this study did
NCT07527858 · Gilead Sciences
2026-05-19 – 2028-12 · Advanced Microsatellite Stable Colorectal Cancer
What this study did
NCT05845450 · Gruppo Oncologico del Nord-Ovest
2023-05-11 – 2028-05 · Colorectal Cancer, Resectable Colorectal Carcinoma
What this study did
NCT04730544 · GERCOR - Multidisciplinary Oncology Cooperative Group
2021-05-21 – 2028-04 · Colorectal Cancer Metastatic, MSI-H Colorectal Cancer
What this study did
NCT07542262 · Blokhin's Russian Cancer Research Center
2025-06-03 – 2028-03-31 · Colorectal Cancer, Gastric Cancer
What this study did
NCT05504252 · University Hospital, Akershus
2022-10-05 – 2028-03-01 · Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma
What this study did
NCT05308446 · National Cancer Institute (NCI)
2022-07-19 – 2027-06-01 · Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
What this study did
NCT03104439 · Massachusetts General Hospital
2017-05-10 – 2027-04 · Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal Cancer
What this study did
NCT07523763 · Blokhin's Russian Cancer Research Center
2024-03-22 – 2027-03-31 · Colorectal Cancer (MSI-H), Colorectal Cancer (CRC)
What this study did
NCT04963283 · University of Colorado, Denver
2021-06-23 – 2027-02-09 · Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer, Rectal Cancer, Rectal Adenocarcinoma, Colorectal Cancer
What this study did
NCT04457284 · Memorial Sloan Kettering Cancer Center
2020-11-18 – 2026-06-17 · Colorectal Adenocarcinoma
What this study did
NCT05588297 · Shanghai Changzheng Hospital
2022-10 – 2025-10 · Colorectal Cancer Liver Metastases
What this study did
NCT06410534 · National Cancer Institute (NCI)
2025-09-09 – 2025-09-09 · Colorectal Cancer, Gastroesophageal Cancer
What this study did
NCT03981146 · University of Birmingham
2019-08-28 – 2024-11-26 · Colorectal Cancer
What this study did
NCT04072198 · Gruppo Oncologico Italiano di Ricerca Clinica
2019-09-26 – 2024-10-30 · Colorectal Cancer
What this study did
NCT03642067 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-02-12 – 2024-09-18 · Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
What this study did
NCT04575922 · Massachusetts General Hospital
2020-10-05 – 2024-06 · Metastatic Microsatellite Stable Colorectal Cancer
What this study did
NCT03388190 · University Hospital, Akershus
2018-05-29 – 2024-03-18 · Colorectal Cancer Metastatic
What this study did
NCT05350501 · Enterome
2023-03-01 – 2024-01-23 · Colorectal Cancer
What this study did
NCT03800602 · Emory University
2019-01-15 – 2021-09-04 · Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage IVC Colorectal Cancer, Colorectal Cancer Metastatic
What this study did
NCT03647839 · Australasian Gastro-Intestinal Trials Group
2018-09-06 – 2021-04-09 · Colorectal Cancer Metastatic
What this study did
NCT03879811 · Memorial Sloan Kettering Cancer Center
2019-03-13 – 2021-03 · Colorectal Cancer
What this study did
Esophageal Squamous Cell Carcinoma
NCT07152678 · National Taiwan University Hospital
2025-09 – 2028-09 · Esophageal Cancer, Esophageal Squamous Cell Carcinoma
What this study did
NCT04229459 · Baruch Brenner
2020-02-16 – 2027-04-04 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05130684 · National Taiwan University Hospital
2021-02-22 – 2024-03-01 · Locally Advanced Esophageal Squamous Cell Carcinoma
What this study did
NCT03987815 · Samsung Medical Center
2019-08-01 – 2022-07-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT04503967 · Shanghai Zhongshan Hospital
2020-08-01 – 2021-08-01 · Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
What this study did
Gastric Cancer
NCT07432295 · I-Mab Biopharma US Limited
2026-02-11 – 2030-08 · Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
What this study did
NCT06253611 · GERCOR - Multidisciplinary Oncology Cooperative Group
2024-04-16 – 2029-04 · Gastric Cancer
What this study did
NCT03505320 · Astellas Pharma Global Development, Inc.
2018-06-29 – 2028-05-31 · Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin, Pharmacokinetics of Fluorouracil Bolus (5-FU)
What this study did
NCT04757363 · Memorial Sloan Kettering Cancer Center
2021-02-11 – 2027-02 · Esophagogastric Cancer, HER2-Negative
What this study did
NCT03776487 · M.D. Anderson Cancer Center
2019-01-07 – 2026-12-30 · Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Localized Gastric Carcinoma, Localized Gastroesophageal Junction Adenocarcinoma, Pathologic Stage 0 Gastric Cancer AJCC v8, Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage I Gastric Cancer AJCC v8, Pathologic Stage IA Gastric Cancer AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
What this study did
NCT03443856 · European Organisation for Research and Treatment of Cancer - EORTC
2019-07-17 – 2026-06 · Gastric and Esophagogastric Junction Adenocarcinoma
What this study did
NCT04062656 · University Hospital, Essen
2019-09-26 – 2025-06-01 · Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
What this study did
Phase 1/2 (297)
Advanced Metastatic Colorectal Cancer
NCT04017650 · M.D. Anderson Cancer Center
2019-06-14 – 2027-12-30 · BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Progressive Disease, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
What this study did
NCT04599140 · M.D. Anderson Cancer Center
2020-10-14 – 2026-07-31 · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
What this study did
NCT03576963 · University of Southern California
2020-01-30 – 2023-01-30 · Colorectal Adenocarcinoma, CpG Island Methylator Phenotype, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
What this study did
NCT03791398 · Brown University
2019-11-15 – 2021-08-05 · Metastatic Colorectal Cancer
What this study did
NCT03307603 · Case Comprehensive Cancer Center
2018-12 – 2021-03 · Metastatic Colorectal Cancer
What this study did
Colorectal Cancer
NCT05919264 · Parabilis Medicines, Inc.
2023-05-23 – 2027-08-31 · Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
What this study did
NCT03711058 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-01-17 – 2025-06-30 · Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
What this study did
NCT04278144 · Bolt Biotherapeutics, Inc.
2020-02-24 – 2025-02-14 · HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
What this study did
NCT03377361 · Bristol-Myers Squibb
2018-01-31 – 2024-11-04 · Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
What this study did
NCT03184870 · Bristol-Myers Squibb
2017-08-08 – 2023-06-14 · Colorectal Cancer, Pancreatic Cancer
What this study did
NCT04208958 · Vedanta Biosciences, Inc.
2020-01-23 – 2023-02-23 · Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
What this study did
NCT03169777 · ImmunityBio, Inc.
2018-08 – 2021-12-28 · Colorectal Cancer
What this study did
NCT03993626 · Celleron Therapeutics Ltd.
2018-05-22 – 2020-06-15 · Colorectal Neoplasms Malignant
What this study did
Esophageal Squamous Cell Carcinoma
NCT03278626 · NYU Langone Health
2017-06-27 – 2021-05-31 · Esophageal Squamous Cell Carcinoma
What this study did
Gastric Cancer
NCT07818018 · Memorial Sloan Kettering Cancer Center
2026-09-04 – 2029-09-04 · Esophageal Cancer, Advanced Esophageal Cancer, Gastric Cancer, Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Cancer
What this study did
NCT03610711 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-03-06 – 2027-12 · Gastroesophageal Cancer, Immune Checkpoint Inhibition
What this study did
NCT04396821 · Transcenta Therapeutics (Hangzhou) Co., Ltd.
2020-05-28 – 2027-09-30 · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
What this study did
NCT07149090 · Asan Medical Center
2025-11-11 – 2027-07-30 · STOMACH NEOPLASM, Gastric Cancer, Gastric Cancer Adenocarcinoma Metastatic
What this study did
NCT06008925 · CNBG-Virogin Biotech (Shanghai) Ltd.
2022-11-17 – 2026-06 · Metastatic Gastric Cancer
What this study did
NCT05322577 · Amgen
2022-05-17 – 2025-11-21 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT03453164 · Fukushima Medical University
2018-03-28 – 2021-01-31 · Gastric Cancer
What this study did
NCT02999295 · National Cancer Center, Japan
2017-01 – 2019-08 · Gastric Cancer, Gastroesophageal Junction Region (GEJ) Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT04895709 · Bristol-Myers Squibb
2021-05-27 – 2031-08-31 · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
What this study did
NCT02955290 · Roswell Park Cancer Institute
2016-12-22 – 2027-12-09 · Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma
What this study did
NCT06047379 · Neonc Technologies, Inc.
2023-11-01 – 2027-08-31 · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
What this study did
NCT04180371 · BicycleTx Limited
2019-11-07 – 2027-07-31 · Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
What this study did
NCT03247712 · Providence Health & Services
2018-01-15 – 2026-12 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
What this study did
NCT04074967 · Dan Zandberg
2020-06-11 – 2025-12-31 · Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
What this study did
NCT04570839 · Compugen Ltd
2020-08-31 – 2024-05-15 · Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
What this study did
NCT05027204 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2022-03-04 – 2023-12-31 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT03370276 · H. Lee Moffitt Cancer Center and Research Institute
2017-12-20 – 2023-12-23 · Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Paranasal Sinus, Head and Neck Squamous Cell Carcinoma, Squamous Cell Cancer, Head and Neck Carcinoma
What this study did
NCT03317327 · Oslo University Hospital
2017-09-09 – 2022-11-28 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT03435640 · Nektar Therapeutics
2018-03-15 – 2022-05-09 · Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma
What this study did
NCT03633110 · Genocea Biosciences, Inc.
2018-08-29 – 2022-02-28 · Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma
What this study did
NCT03655444 · Washington University School of Medicine
2019-05-29 – 2020-08-24 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT02327078 · Incyte Corporation
2014-11-26 – 2020-06-16 · B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma
What this study did
NCT02842125 · MultiVir, Inc.
2018-11-20 – 2020-05-08 · Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
What this study did
NCT02335918 · Celldex Therapeutics
2015-01 – 2018-12-12 · Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
What this study did
Hepatocellular Carcinoma
NCT07482059 · West China Hospital
2026-02 – 2028-06-30 · Unresectable Hepatocellular Carcinoma
What this study did
NCT04380545 · M.D. Anderson Cancer Center
2021-01-13 – 2028-02-28 · Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Fibrolamellar Carcinoma
What this study did
NCT03682276 · Imperial College London
2019-03-01 – 2026-03-12 · Hepatocellular Carcinoma
What this study did
NCT05337137 · Bristol-Myers Squibb
2022-05-05 – 2025-11-18 · Carcinoma, Hepatocellular
What this study did
NCT05220722 · TriSalus Life Sciences, Inc.
2022-03-02 – 2024-07-31 · Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
What this study did
NCT04170556 · Fundacion Clinic per a la Recerca Biomédica
2020-03-16 – 2024-07-09 · Hepatocellular Carcinoma
What this study did
NCT04233840 · National Taiwan University Hospital
2019-02-12 – 2023-07-31 · Hepatocellular Carcinoma
What this study did
NCT03893695 · Suzhou Kintor Pharmaceutical Inc,
2019-05-25 – 2022-09-27 · Metastatic Hepatocellular Carcinoma, HCC, Combinations of Drugs; Dependence
What this study did
NCT03684811 · Forma Therapeutics, Inc.
2018-11-01 – 2022-06-13 · Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
What this study did
Phase 1 (393)
Advanced Metastatic Colorectal Cancer
NCT04362839 · City of Hope Medical Center
2020-05-27 – 2025-12-11 · Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8
What this study did
NCT03712943 · H. Lee Moffitt Cancer Center and Research Institute
2018-10-23 – 2024-01-18 · Colorectal Cancer, Metastatic Colorectal Cancer, Colon Cancer
What this study did
NCT04044430 · University of California, San Francisco
2020-08-31 – 2022-07-31 · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer, Stage III Colorectal Cancer, Stage III Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Rectal Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Colorectal Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Colorectal Cancer, Stage IVB Rectal Cancer, Stage IVC Colon Cancer, Stage IVC Colorectal Cancer, Stage IVC Rectal Cancer
What this study did
NCT03507699 · Sheba Medical Center
2018-12-15 – 2022-05-25 · Colorectal Neoplasms Malignant, Liver Metastases
What this study did
NCT02848443 · Institut de Recherches Internationales Servier
2016-05 – 2020-04-09 · Metastatic Colorectal Cancer
What this study did
Colorectal Cancer
NCT06540261 · Ono Pharmaceutical Co., Ltd.
2021-09-23 – 2027-12-31 · Unresectable Colorectal Cancer
What this study did
NCT06547385 · Ono Pharmaceutical Co., Ltd.
2021-01-13 – 2027-10-31 · Colorectal Cancer
What this study did
NCT04117087 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020-05-28 – 2027-06-01 · Colorectal Cancer, Pancreatic Cancer
What this study did
NCT04721301 · University Hospital Heidelberg
2017-01-15 – 2023-03-15 · Colorectal Cancer Metastatic, Pancreatic Cancer Metastatic
What this study did
NCT03373188 · Emory University
2017-12-15 – 2021-10-28 · Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
What this study did
NCT03982121 · Gustave Roussy, Cancer Campus, Grand Paris
2019-06-04 – 2020-02-12 · Colorectal Cancer Metastatic
What this study did
NCT02991196 · Daiichi Sankyo
2016-12-01 – 2017-09-22 · Colorectal Neoplasm
What this study did
Esophageal Squamous Cell Carcinoma
NCT03914443 · National Cancer Center, Japan
2019-05-07 – 2025-03-31 · Locally Advanced Esophageal Squamous Cell Carcinoma
What this study did
Gastric Cancer
NCT05802056 · Mayo Clinic
2023-11-29 – 2029-06-24 · Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum
What this study did
NCT05187182 · Washington University School of Medicine
2023-06-02 – 2029-04-30 · Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
What this study did
NCT04900818 · I-Mab Biopharma US Limited
2021-06-29 – 2027-12 · Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
What this study did
NCT03044613 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2017-07-11 – 2027-08 · Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer
What this study did
NCT03784040 · National University Hospital, Singapore
2019-02-21 – 2024-03-01 · Gastric Cancer
What this study did
NCT02946671 · Osaka University
2016-03 – 2020-03 · Gastric Cancer, Esophageal Cancer, Lung Cancer, Renal Cancer, Oral Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT04044859 · USWM CT, LLC
2019-08-20 – 2037-04-30 · Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
What this study did
NCT05076760 · Memgen, Inc.
2022-04-21 – 2031-12 · Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
What this study did
NCT07741565 · Vanderbilt-Ingram Cancer Center
2026-10-30 – 2031-09-30 · HNSCC, SCC - Squamous Cell Carcinoma, Oral Cancer
What this study did
NCT07460765 · Vanderbilt-Ingram Cancer Center
2026-07-03 – 2031-04 · Hnscc, Head and Neck, Squamous Cell Cancer, Squamous Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma Mouth, Squamous Carcinoma Poorly Differentiated, Squamous Cell Cancer of the Head and Neck, Squamous Cell Carcinoma (SCC) of the Oral Cavity, Squamous Cell Carcinoma (SCC)
What this study did
NCT05176483 · Exelixis
2021-12-14 – 2030-06-28 · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
What this study did
NCT07216833 · Case Comprehensive Cancer Center
2026-01 – 2027-12-31 · Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
What this study did
NCT03690986 · Emory University
2018-11-01 – 2027-11-30 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT03589339 · Nanobiotix
2019-01-16 – 2027-08-30 · Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
What this study did
NCT05327270 · M.D. Anderson Cancer Center
2022-09-13 – 2027-02-02 · Head and Neck Cancer
What this study did
NCT06357858 · Case Comprehensive Cancer Center
2024-06-01 – 2026-02-28 · Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT06034860 · Molecular Templates, Inc.
2023-11-01 – 2024-10-31 · Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
What this study did
NCT03727061 · Roswell Park Cancer Institute
2019-07-10 – 2024-10-22 · Recurrent Head and Neck Carcinoma, Locally Advanced Head and Neck Carcinoma
What this study did
NCT04659369 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2020-09-24 – 2023-10-16 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT05395052 · Fate Therapeutics
2022-05-31 – 2023-08-11 · Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
What this study did
NCT05472506 · Ikena Oncology
2023-03 – 2023-04 · Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head Cancer, Neck Cancer, Head Cancer Neck, Neck Carcinoma
What this study did
NCT03162731 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2017-05-11 – 2022-11-16 · Larynx, Lip, Oral Cavity and Pharynx
What this study did
NCT03841110 · Fate Therapeutics
2019-02-15 – 2022-11-15 · Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
What this study did
NCT03652233 · Vanderbilt-Ingram Cancer Center
2018-11-02 – 2022-11 · Recurrent Squamous Cell Carcinoma of the Head or Neck, Metastatic Squamous Cell Carcinoma of the Head or Neck, Squamous Cell Carcinoma
What this study did
NCT03229278 · Rutgers, The State University of New Jersey
2017-10-03 – 2022-10-30 · Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
What this study did
NCT03735628 · Bayer
2018-10-17 – 2022-10-13 · Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC)
What this study did
NCT03238365 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2017-08-10 – 2022-09-08 · Lip, Oral Cavity and Pharynx, Larynx
What this study did
NCT03829436 · Tempest Therapeutics
2019-03-20 – 2022-09-07 · Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
What this study did
NCT02764593 · RTOG Foundation, Inc.
2016-06 – 2022-02-21 · Head and Neck Squamous Cell Carcinoma (HNSCC)
What this study did
NCT03906526 · Celgene
2019-07-03 – 2022-01-24 · Carcinoma, Squamous Cell
What this study did
NCT02636036 · Akamis Bio
2016-01-25 – 2021-10-08 · Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
What this study did
NCT03758781 · H. Lee Moffitt Cancer Center and Research Institute
2019-02-13 – 2021-08-11 · Metastatic Cancer, Recurrent Cancer, Solid Tumor, Renal Cell Carcinoma, Urothelial Carcinoma, NSCLC, Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT03575598 · University Health Network, Toronto
2018-08-30 – 2020-02-18 · Squamous Cell Carcinoma, Head And Neck, Squamous Cell Carcinoma Mouth, Squamous Cell Carcinoma of the Oral Cavity
What this study did
NCT02526017 · Five Prime Therapeutics, Inc.
2015-09-08 – 2019-11-18 · Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
What this study did
NCT02124850 · Celgene
2014-10-28 – 2016-10-31 · Squamous Cell Carcinoma of the Head and Neck
What this study did
Hepatocellular Carcinoma
NCT04248569 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020-04-20 – 2034-03-01 · Fibrolamellar Hepatocellular Carcinoma (FLC)
What this study did
NCT07430202 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2026-10-28 – 2030-10 · Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
What this study did
Phase 4 (16)
Melanoma
NCT07459543 · Bristol-Myers Squibb
2026-11-15 – 2029-05-28 · Unresectable Melanoma, Metastatic Melanoma
What this study did
NCT06116461 · Erasmus Medical Center
2022-01-05 – 2025-01 · Melanoma
What this study did
NCT02626065 · Hospices Civils de Lyon
2015-04-23 – 2017-12-28 · Metastatic Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT03313544 · Assistance Publique Hopitaux De Marseille
2018-04-09 – 2025-03 · Melanoma, Non-small Cell, Lung Cancer
What this study did
NCT05583188 · Galvanize Therapeutics, Inc.
2023-02-01 – 2024-03-18 · NSCLC
What this study did
NCT04331626 · Henan Cancer Hospital
2020-04 – 2023-04 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT03444766 · Bristol-Myers Squibb
2018-03-06 – 2019-07-17 · Non-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms
What this study did
Renal Cell Carcinoma
NCT07872553 · Memorial Sloan Kettering Cancer Center
2026-09-24 – 2030-09-24 · Renal Cell Carcinoma, Kidney Cancer
What this study did
NCT07028125 · Centre Francois Baclesse
2025-10-01 – 2029-01 · Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma, Locally Advanced
What this study did
NCT06934057 · Gustave Roussy, Cancer Campus, Grand Paris
2025-05-16 – 2028-04 · Kidney Cancer, Renal Cell Cancer
What this study did
NCT02982954 · Bristol-Myers Squibb
2017-01-16 – 2021-10-06 · Renal Cell Carcinoma
What this study did
NCT02596035 · Bristol-Myers Squibb
2016-01-08 – 2021-05-24 · Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT06031233 · Isala
2023-09-01 – 2028-12 · Oncology, Infusion Reaction
What this study did
NCT04513522 · Bristol-Myers Squibb
2020-12-17 – 2024-01-04 · Kidney Neoplasms
What this study did
NCT02869789 · Bristol-Myers Squibb
2016-10-05 – 2022-05-13 · Lung Cancer
What this study did
Early phase / not applicable (24)
Gastric Cancer
NCT05001360 · Fujian Cancer Hospital
2021-10 – 2023-11 · Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma, Esophagus Adenocarcinoma
What this study did
NCT05053295 · Gangnam Severance Hospital
2021-07-02 – 2023-09-30 · Relapsed or Advanced Gastric Adenocarcinoma, Gastro-esophageal Junction Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT04603248 · Yonsei University
2020-12-03 – 2026-03-18 · Head and Neck Squamous Cell Carcinoma (HNSCC)
What this study did
NCT05821751 · Fondazione del Piemonte per l'Oncologia
2021-12-02 – 2025-12-02 · Head and Neck Squamous Cell Carcinoma
What this study did
Hepatocellular Carcinoma
NCT07053202 · The First Hospital of Hebei Medical University
2021-10-01 – 2023-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
Melanoma
NCT05652673 · Erasmus Medical Center
2023-02-01 – 2029-12-01 · Melanoma Stage IV, Melanoma Stage III, Immunotherapy, Toxicity, Drug
What this study did
NCT07564570 · Universitätsklinikum Hamburg-Eppendorf
2025-11-14 – 2028-12-31 · Metastatic Melanoma
What this study did
NCT07364474 · Massachusetts General Hospital
2026-01-27 – 2028-09 · Uveal Melanoma
What this study did
NCT07422779 · Institute of Oncology Ljubljana
2022-03-01 – 2028-03-31 · Metastatic Melanoma, Skin Cancer
What this study did
NCT07436390 · Institute of Oncology Ljubljana
2024-03-31 – 2024-03-31 · Metastatic Melanoma, Malignant Melanoma, Skin Cancer
What this study did
NCT03225365 · Hospices Civils de Lyon
2019-10-10 – 2021-06-15 · Metastatic Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT02194738 · National Cancer Institute (NCI)
2014-09-26 – 2027-09-21 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT03564197 · The Netherlands Cancer Institute
2018-10-25 – 2026-01-30 · NSCLC Stage IV
What this study did
Renal Cell Carcinoma
NCT07233668 · Seoul National University Hospital
2025-12-01 – 2029-02-01 · Metastatic Renal Cell Carcinoma ( mRCC)
What this study did
NCT05119010 · Gustave Roussy, Cancer Campus, Grand Paris
2023-03-24 – 2024-05-22 · Metastatic Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT06519682 · Daniel Morgenstern
2024-12-06 – 2029-08 · High Grade Glioma, Replication Repair Deficient
What this study did
NCT05745233 · China Medical University Hospital
2021-01-01 – 2026-12 · Malignant Ascites
What this study did
NCT05533983 · Asan Medical Center
2023-03-08 – 2026-08-19 · Solid Carcinoma
What this study did
NCT04256213 · ARCAGY/ GINECO GROUP
2020-07-02 – 2024-08-04 · Cervix Cancer
What this study did
NCT02833233 · Memorial Sloan Kettering Cancer Center
2016-06 – 2024-06-07 · Breast Cancer
What this study did
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
NCT04845139 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-02 – 2022-11-30 · Refractory Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Primary Central Nervous System Lymphoma
What this study did
Used as active comparator (40)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (14)
Esophageal Squamous Cell Carcinoma
NCT06022861 · Shandong Boan Biotechnology Co., Ltd
2023-10-12 – 2026-10-30 · Esophageal Squamous Cell Carcinoma
What this study did
Gastric Cancer
NCT06346197 · Centre Leon Berard
2025-12-08 – 2028-05-15 · Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer
What this study did
Melanoma
NCT06246916 · Regeneron Pharmaceuticals
2024-09-09 – 2033-07-10 · Melanoma
What this study did
NCT06743126 · Immatics US, Inc.
2025-01-14 – 2032-08-12 · Melanoma, Cutaneous Malignant, Mucosal Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07195695 · Boehringer Ingelheim
2026-01-16 – 2036-09-02 · Non-small Cell Lung Cancer
What this study did
NCT07672223 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-07-30 – 2031-11-30 · Non-small Cell Lung Cancer
What this study did
NCT06908993 · Intergroupe Francophone de Cancerologie Thoracique
2025-12-09 – 2028-07-15 · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
What this study did
Urothelial Carcinoma
NCT07720284 · AstraZeneca
2026-07-16 – 2032-11-23 · High-risk Muscle Invasive Urothelial Carcinoma
What this study did
Other / comorbidity
NCT06097728 · AstraZeneca
2023-11-09 – 2028-11-16 · Unresectable Pleural Mesothelioma
What this study did
NCT04334759 · PrECOG, LLC.
2021-02-18 – 2025-06-30 · Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
What this study did
Phase 2/3 (5)
Gastric Cancer
NCT07392892 · Pfizer
2026-05-14 – 2032-07-21 · Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
What this study did
Melanoma
NCT06624644 · Linnaeus Therapeutics, Inc.
2025-08-06 – 2031-02 · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
What this study did
NCT05987332 · IDEAYA Biosciences
2023-10-31 – 2028-01-15 · Metastatic Uveal Melanoma
What this study did
Other / comorbidity
NCT06879145 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-04-25 – 2031-12 · Muscular Invasive Bladder Cancer (MIBC)
What this study did
Phase 2 (15)
Esophageal Squamous Cell Carcinoma
NCT04785820 · Hoffmann-La Roche
2021-06-25 – 2025-01-30 · Advanced or Metastatic Esophageal Squamous Cell Carcinoma
What this study did
Gastric Cancer
NCT03704077 · Bristol-Myers Squibb
2019-10-31 – 2024-09-30 · Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
What this study did
Hepatocellular Carcinoma
NCT04393220 · Fuda Cancer Hospital, Guangzhou
2020-05-11 – 2021-08-31 · Progress Free Survival (PFS) and Overall Survival (OS)
What this study did
Melanoma
NCT04462406 · ECOG-ACRIN Cancer Research Group
2021-02-09 – 2030-09-30 · Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
What this study did
NCT02523313 · Prof. Dr. med. Dirk Schadendorf
2015-09-02 – 2021-06-27 · Malignant Melanoma
What this study did
NCT02054520 · NewLink Genetics Corporation
2014-06 – 2021-01-05 · Stage IV Melanoma, Metastatic Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07398937 · Fudan University
2026-02-05 – 2029-12-31 · Resectable Stage II-IIIa Squamous NSCLC
What this study did
NCT05633667 · Gilead Sciences
2023-03-16 – 2029-09 · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
What this study did
NCT04758949 · Flame Biosciences
2021-08-25 – 2021-12-22 · Non-Small Cell Lung Cancer
What this study did
NCT02852083 · University Hospital Regensburg
2016-01 – 2020-07 · Squamous Cell Lung Cancer, Non-Squamous Cell Lung Cancer, Non-Small Cell Lung Cancer
What this study did
Renal Cell Carcinoma
NCT07188896 · Brian Rini
2026-04-29 – 2030-11-30 · Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)
What this study did
NCT07877194 · Summit Therapeutics
2026-10-19 – 2029-12-12 · Renal Cell Carcinoma, Clear Cell
What this study did
NCT05928806 · Michael B. Atkins, MD
2023-09-25 – 2027-11-10 · Advanced Renal Cell Carcinoma
What this study did
Phase 1/2 (4)
Melanoma
NCT05116202 · Hoffmann-La Roche
2022-02-02 – 2024-05-28 · Melanoma
What this study did
Renal Cell Carcinoma
NCT02118337 · MedImmune LLC
2014-05-19 – 2020-03-17 · Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT04187404 · Enterome
2020-07-23 – 2024-10-02 · Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
What this study did
Phase 1 (1)
Urothelial Carcinoma
NCT07518043 · Shanghai Henlius Biotech
2026-07-15 – 2028-06-13 · Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)
What this study did
Phase 4 (1)
Other / comorbidity
NCT04707547 · Taipei Medical University WanFang Hospital
2019-10-16 – 2020-07-23 · Liver Cancer
What this study did
Appears in other studies (37)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (8)
Gastric Cancer
NCT07818070 · Ono Pharmaceutical Co., Ltd.
2027-02 – 2031-01 · Gastric Cancer, Esophagogastric Junction Cancer, Esophageal Adenocarcinoma
What this study did
NCT05111626 · Amgen
2022-03-14 – 2025-10-29 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
Hepatocellular Carcinoma
NCT07166406 · NRG Oncology
2026-02-26 – 2034-03-10 · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
What this study did
Melanoma
NCT07815574 · Scancell Ltd
2026-12-01 – 2032-12-01 · Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05317858 · InSightec
2022-08-12 – 2031-12-01 · Brain Tumor, Non Small Cell Lung Cancer
What this study did
Renal Cell Carcinoma
NCT07383441 · SWOG Cancer Research Network
2026-06-05 – 2034-01-31 · Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT03793166 · National Cancer Institute (NCI)
2019-06-07 – 2028-03-01 · Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT03937219 · Exelixis
2019-06-25 – 2027-01-31 · Renal Cell Carcinoma
What this study did
Phase 2/3 (1)
Other / comorbidity
Phase 2 (21)
Colorectal Cancer
NCT07403877 · Fudan University
2026-02-01 – 2034-12-31 · Colorectal Cancer (MSI-H)
What this study did
Gastric Cancer
Head and Neck Squamous Cell Carcinoma
NCT07529873 · Groupe Oncologie Radiotherapie Tete et Cou
2026-03-03 – 2030-12 · Squamous Cell Carcinoma of Head and Neck (SCCHN)
What this study did
NCT03511391 · University Hospital, Ghent
2018-03-09 – 2024-01-23 · Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Head and Neck Cancer
What this study did
Melanoma
NCT03646617 · Abramson Cancer Center at Penn Medicine
2018-11-27 – 2027-12-31 · Metastatic Melanoma
What this study did
NCT03693014 · Memorial Sloan Kettering Cancer Center
2018-10-01 – 2027-10 · Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
What this study did
Non-Small Cell Lung Cancer
NCT07603856 · University of Chicago
2026-12-12 – 2030-06-25 · Non-Small Cell Lung Cancer, Metastatic Lung Cancer
What this study did
NCT05500092 · Montefiore Medical Center
2023-01-25 – 2030-05 · Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
What this study did
NCT06463665 · Genelux Corporation
2024-09-26 – 2029-07 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
NCT06554613 · Second Affiliated Hospital of Nanchang University
2024-07-02 – 2027-05-31 · Non-Small Cell Lung Cancer
What this study did
NCT02664181 · Case Comprehensive Cancer Center
2017-06-06 – 2024-05-19 · Lung Cancer, Non-small Cell Lung Cancer
What this study did
NCT03468985 · National Cancer Institute (NCI)
2018-05-07 – 2022-12-21 · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT03382912 · Eli Lilly and Company
2018-03-22 – 2020-03-03 · Non Small Cell Lung Cancer
What this study did
Renal Cell Carcinoma
NCT05327686 · NRG Oncology
2023-02-01 – 2033-06-15 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
What this study did
NCT05817903 · Consorzio Oncotech
2023-04-18 – 2027-04-01 · Metastatic Renal Cell Carcinoma
What this study did
Urothelial Carcinoma
NCT06534983 · Hoffmann-La Roche
2024-12-09 – 2027-11-10 · Muscle-invasive Urothelial Carcinoma
What this study did
Other / comorbidity
NCT05836571 · National Cancer Institute LAO
2023-10-25 – 2028-05-15 · Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
What this study did
NCT03038672 · National Cancer Institute (NCI)
2018-12-21 – 2027-10-23 · ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
What this study did
NCT06059547 · CatalYm GmbH
2023-09-06 – 2026-06-05 · Bladder Cancer, Adult Solid Tumor
What this study did
NCT02864381 · Gilead Sciences
2016-09-01 – 2019-08-23 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 1/2 (3)
Non-Small Cell Lung Cancer
NCT02466568 · H. Lee Moffitt Cancer Center and Research Institute
2018-07 – 2020-07 · Lung Cancer, Adenocarcinoma of the Lung
What this study did
NCT02924233 · Symphogen A/S
2016-11 – 2017-02 · Squamous Non-Small Cell Lung Cancer
What this study did
Phase 1 (3)
Melanoma
NCT03293784 · Institut Claudius Regaud
2017-10-16 – 2023-08-10 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT03732664 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2018-10-01 – 2023-03-23 · High-Risk Resectable NSCLC
What this study did
Other / comorbidity
NCT03728179 · Centre Hospitalier Universitaire Vaudois
2019-01-16 – 2023-10-27 · Solid Tumor, Adult
What this study did
Early phase / not applicable (1)
Gastric Cancer
NCT06158919 · Fudan University
2023-11-20 – 2026-11-20 · Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nivolumab: this drugApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
BAT3306Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRPartial signal
NCT06380348: Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24).
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT04471428: Overall Survival (OS) (Up to approximately 24 months): Atezolizumab + Cabozantinib 10.7 months (95% CI 8.8 to 12.3) vs Docetaxel Monotherapy 10.5 months (95% CI 8.6 to 13) missed
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4Weak signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
CT-P51Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-APartial signal
NCT03952403: ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC.
IBI305Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT02954172: Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33.
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890
Phase 3(overall)
Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Iparomlimab And TuvonralimabPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAReliable signal
NCT05499390: HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized
NCT05184712: HARMONi-A (NCT05184712), independent-review PFS: ivonescimab plus chemotherapy 7.1 vs placebo plus chemotherapy 4.8 months; HR 0.46 (95% CI 0.34-0.62), P<.001
IzalontamabPhase 3Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT03533127: LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated.
MB12Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
RelatlimabPhase 3Monoclonal antibodyLAG-3Partial signal
NCT04623775: Part 2 objective response rate by BICR (RECIST 1.1): nivolumab + relatlimab + chemotherapy 50.6% (90% CI 43.8 to 57.4, n=158) vs nivolumab + chemotherapy 43.0% (90% CI 36.2 to 50.1, n=151); odds ratio 1.39 (90% CI 0.94 to 2.05). The Part 1 co-primary (TRAEs leading to discontinuation within 12 weeks) compares two relatlimab regimens: 5.6% vs 12.1% (CT.gov posted results). missed
RetifanlimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
Retlirafusp AlfaPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signalNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed
Savolitinib (Orpathys)Phase 3Small moleculeMETPartial signal
NCT05261399: SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib.
NCT05015608: Median PFS (SACHI trial, ITT): 8.2 months savolitinib+osimertinib vs 4.5 months chemotherapy; in patients prior on 1st/2nd-gen EGFR-TKI: 9.8 vs 5.4 months; predefined significance thresholds met in both populations
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
SintilimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
ToripalimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT03856411: Median PFS: 8.4 months (toripalimab plus chemotherapy) vs 5.6 months (placebo plus chemotherapy); HR 0.49 (95% CI 0.39-0.61), P<0.0001
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4Partial signal
NCT05984277: Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). missed
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
LNS8801
Phase 2/3(overall)
Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
SasanlimabPhase 2/3Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only in this race
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 2Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 2Small moleculeHDACWeak signal
NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
Erdafitinib (Balversa)Phase 2Small moleculeFGFR1-4Weak signal
NCT02699606: NSCLC cohort (n=12): objective response rate 0% (no CR or PR); disease control rate 25.0% (95% CI 5.5-57.2%); 3 patients stable disease, 2 with tumor shrinkage >20%. missed
Ifinatamab DeruxtecanPhase 2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
NBTXR3Phase 2NanoparticleHafnium-oxide nanoparticle radioenhancernot yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
OrdastobartPhase 2Monoclonal antibodyOX40 (agonist)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)Phase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
ASP546CPhase 1/2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
BafisontamabPhase 1/2Multispecific antibodyEGFR x c-METWeak signalFeatured results are dose-finding only in this race
BGB-B2033Phase 1/2Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 1/2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
IOV-4001Phase 1/2Cell therapyPD-1not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 1/2PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 1/2Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
OSE-279Phase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Ozuriftamab VedotinPhase 1/2Antibody–drug conjugateROR2Partial signalNo reviewed efficacy summary in this indication
Precemtabart TocentecanPhase 1/2Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 1/2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 1/2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
AfivastobartPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
AKY-1189Phase 1RadiopharmaceuticalNectin-4 (PVRL4)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T CellPhase 1Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY4052031Phase 1Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
ONO-4578Phase 1Small moleculeProstaglandin E2 receptor 4 (EP4)not yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
BuparlisibDiscontinuedSmall moleculePI3K inhibitor (pan-class I)not yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFWeak signal
NCT02607813: 142 patients were treated across the naporafenib dose-escalation (n = 87), naporafenib plus spartalizumab dose-escalation (n = 12) and dose-expansion (n = 43) arms. The maximum tolerated and recommended dose for single-agent naporafenib was 600 mg twice daily. Five patients in the naporafenib escalation arm had 7 dose-limiting toxicities, including decreased platelet count at 1200 mg once daily, neuralgia, maculopapular rash and pruritus at 600 mg twice daily, and increased blood bilirubin, hyponatremia and peripheral sensory neuropathy at 800 mg twice daily.

Large race: only the 158 furthest-along competitors are listed; 455 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(383 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nivolumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (46)
November 2026 (5)
Phase 1/2Hodgkin LymphomaRecruiting
Est. primary completion 2026-11 · NCT03681561 · CT.gov ↗
What to watch
Phase 2GlioblastomaActive not recruiting
Est. primary completion 2026-11 · NCT03743662 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2026-11 · NCT06712927 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-25 · NCT02955290 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorActive not recruiting
Est. primary completion 2026-11-30 · NCT04735978 · CT.gov ↗
What to watch
December 2026 (41)
Phase 1Gastric CancerRecruiting
Est. primary completion 2026-12 · NCT04900818 · CT.gov ↗
What to watch
Phase 1Stage IV Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03223155 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12 · NCT07176650 · CT.gov ↗
What to watch
Phase 1/2MelanomaActive not recruiting
Est. primary completion 2026-12 · NCT04283890 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerActive not recruiting
Est. primary completion 2026-12 · NCT03610711 · CT.gov ↗
What to watch
Phase 1/2Prostate CancerActive not recruiting
Est. primary completion 2026-12 · NCT04989946 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of the SkinRecruiting
Est. primary completion 2026-12 · NCT04204837 · CT.gov ↗
What to watch
Phase 2Merkel Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06151236 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03527108 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaActive not recruiting
Est. primary completion 2026-12 · NCT05723055 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT05476796 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05263050 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12 · NCT04912765 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2026-12 · NCT03340129 · CT.gov ↗
What to watch
Phase 3Metastatic Colon Cancer, Stage III Colon CancerActive not recruiting
Est. primary completion 2026-12 · NCT03803553 · CT.gov ↗
What to watch
Early phase / not applicableMalignant AscitesEnrolling by invitation
Est. primary completion 2026-12 · NCT05745233 · CT.gov ↗
What to watch
Early phase / not applicableHigh Grade Glioma, Replication Repair DeficientRecruiting
Est. primary completion 2026-12 · NCT06519682 · CT.gov ↗
What to watch
Phase 1Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated LymphomasRecruiting
Est. primary completion 2026-12-01 · NCT04902443 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT06682728 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2026-12-01 · NCT06237920 · CT.gov ↗
What to watch
Phase 2Pleural Biphasic Mesothelioma, Pleural Sarcomatoid MesotheliomaRecruiting
Est. primary completion 2026-12-15 · NCT05647265 · CT.gov ↗
What to watch
Phase 3Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-15 · NCT05678673 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-20 · NCT04413123 · CT.gov ↗
What to watch
Phase 1Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV AstrocytomaActive not recruiting
Est. primary completion 2026-12-30 · NCT04606316 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2026-12-30 · NCT03259867 · CT.gov ↗
What to watch
Phase 2Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract, Penile Cancer …Active not recruiting
Est. primary completion 2026-12-30 · NCT03333616 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT03776487 · CT.gov ↗
What to watch
Phase 1Leptomeningeal DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT05112549 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT05234307 · CT.gov ↗
What to watch
Phase 1MelanomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04835805 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT02210117 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2026-12-31 · NCT03685890 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04180371 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT05597800 · CT.gov ↗
What to watch
Phase 2Uterine Cervical NeoplasmsRecruiting
Est. primary completion 2026-12-31 · NCT05492123 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2026-12-31 · NCT07155317 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05257590 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04953104 · CT.gov ↗
What to watch
Phase 2Rectal Cancer Stage II, Rectal Cancer Stage IIIActive not recruiting
Est. primary completion 2026-12-31 · NCT04503694 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT02451982 · CT.gov ↗
What to watch
2027 (175)
January 2027 (15)
Phase 1/2Sarcoma, Solid Tumor, Adult, Solid Tumor, ChildhoodRecruiting
Est. primary completion 2027-01 · NCT03465592 · CT.gov ↗
What to watch
Phase 1/2Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-01 · NCT03033914 · CT.gov ↗
What to watch
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2027-01 · NCT03520491 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-01 · NCT05280457 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-01 · NCT03104439 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-01 · NCT06731270 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-01-01 · NCT05136196 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-01-12 · NCT05122546 · CT.gov ↗
What to watch
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-01-19 · NCT05584670 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-01-23 · NCT06250335 · CT.gov ↗
What to watch
Phase 1HER2-Expressing Solid TumorsRecruiting
Est. primary completion 2027-01-31 · NCT07334119 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT05176483 · CT.gov ↗
What to watch
Phase 1Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8Active not recruiting
Est. primary completion 2027-01-31 · NCT03816358 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-01-31 · NCT04079166 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-01-31 · NCT04472767 · CT.gov ↗
What to watch
February 2027 (14)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02 · NCT05076760 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-02 · NCT04757363 · CT.gov ↗
What to watch
Phase 1/2Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors …Active not recruiting
Est. primary completion 2027-02-01 · NCT05407441 · CT.gov ↗
What to watch
Phase 2Metastatic Soft-tissue SarcomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04551430 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-02-02 · NCT05327270 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02-05 · NCT06946797 · CT.gov ↗
What to watch
Phase 1GlioblastomaActive not recruiting
Est. primary completion 2027-02-15 · NCT04047706 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-02-15 · NCT06319196 · CT.gov ↗
What to watch
Phase 2Classical Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-02-15 · NCT02940301 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT05267626 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT06047379 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT06275360 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8Recruiting
Est. primary completion 2027-02-28 · NCT07226856 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-02-28 · NCT03866382 · CT.gov ↗
What to watch
March 2027 (17)
Phase 1Gastric CancerActive not recruiting
Est. primary completion 2027-03 · NCT03044613 · CT.gov ↗
What to watch
Phase 1/2B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in RelapseRecruiting
Est. primary completion 2027-03 · NCT05310591 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-03 · NCT05239533 · CT.gov ↗
What to watch
Phase 1NeoplasmsActive not recruiting
Est. primary completion 2027-03-01 · NCT02817633 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-03-01 · NCT06983210 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-03-02 · NCT03655002 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2027-03-04 · NCT05498792 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-03-11 · NCT05289193 · CT.gov ↗
What to watch
Phase 3Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-03-11 · NCT03873402 · CT.gov ↗
What to watch
Phase 1/2Grade 2 Meningioma, Grade 3 Meningioma, Recurrent MeningiomaActive not recruiting
Est. primary completion 2027-03-19 · NCT03604978 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
Phase 1/2Solid NeoplasmsActive not recruiting
Est. primary completion 2027-03-31 · NCT04078295 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT04310007 · CT.gov ↗
What to watch
Phase 2Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8Recruiting
Est. primary completion 2027-03-31 · NCT06064097 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT03391869 · CT.gov ↗
What to watch
Phase 3Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2027-03-31 · NCT04444921 · CT.gov ↗
What to watch
Early phase / not applicableMelanomaRecruiting
Est. primary completion 2027-03-31 · NCT07422779 · CT.gov ↗
What to watch
April 2027 (17)
Phase 1MelanomaRecruiting
Est. primary completion 2027-04 · NCT04741997 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-04 · NCT04730544 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-04 · NCT04848116 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-04 · NCT03122522 · CT.gov ↗
What to watch
Phase 3MelanomaRecruiting
Est. primary completion 2027-04 · NCT07221734 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-01 · NCT05254184 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2027-04-01 · NCT05919264 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2027-04-05 · NCT03097939 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaRecruiting
Est. primary completion 2027-04-07 · NCT07187869 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-04-09 · NCT03690986 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04-09 · NCT02393625 · CT.gov ↗
What to watch
Phase 1/2Solid Tumor, Metastases to Soft TissueActive not recruiting
Est. primary completion 2027-04-23 · NCT03707808 · CT.gov ↗
What to watch
Phase 1Gastric CancerActive not recruiting
Est. primary completion 2027-04-24 · NCT05802056 · CT.gov ↗
What to watch
Phase 1Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-04-27 · NCT05162976 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-27 · NCT06364917 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04-30 · NCT03589339 · CT.gov ↗
What to watch
Phase 2Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm …Active not recruiting
Est. primary completion 2027-04-30 · NCT03449108 · CT.gov ↗
What to watch
May 2027 (9)
Phase 2MelanomaRecruiting
Est. primary completion 2027-05 · NCT05384496 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-05 · NCT04322955 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-05 · NCT05845450 · CT.gov ↗
What to watch
Phase 2Muscle-Invasive Bladder CarcinomaActive not recruiting
Est. primary completion 2027-05 · NCT04506554 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-01 · NCT06265285 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-05-12 · NCT07919717 · CT.gov ↗
What to watch
Phase 2Premalignant LesionRecruiting
Est. primary completion 2027-05-30 · NCT06561087 · CT.gov ↗
What to watch
Phase 2Metastatic Malignant Solid Neoplasm, Unresectable Solid NeoplasmActive not recruiting
Est. primary completion 2027-05-31 · NCT04957615 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05-31 · NCT02595944 · CT.gov ↗
What to watch
June 2027 (21)
Phase 1Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2027-06 · NCT05733689 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT05681780 · CT.gov ↗
What to watch
Phase 2MesotheliomaActive not recruiting
Est. primary completion 2027-06 · NCT03918252 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT06015724 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-06 · NCT03546686 · CT.gov ↗
What to watch
Phase 1Recurrent GlioblastomaActive not recruiting
Est. primary completion 2027-06-01 · NCT06097975 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT04117087 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT03025256 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-06-09 · NCT05912244 · CT.gov ↗
What to watch
Phase 1Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma …Recruiting
Est. primary completion 2027-06-28 · NCT05272384 · CT.gov ↗
What to watch
Phase 1Metastatic Pancreatic CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT06532344 · CT.gov ↗
What to watch
Phase 1/2Advanced CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT04495296 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT04396821 · CT.gov ↗
What to watch
Phase 1/2Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT01896999 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-06-30 · NCT04831320 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-06-30 · NCT05034536 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03505320 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-06-30 · NCT04511013 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8Active not recruiting
Est. primary completion 2027-06-30 · NCT04751370 · CT.gov ↗
What to watch
Phase 2Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary GlioblastomaActive not recruiting
Est. primary completion 2027-06-30 · NCT04145115 · CT.gov ↗
What to watch
Phase 3Primary Mediastinal Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT04759586 · CT.gov ↗
What to watch
July 2027 (9)
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-07 · NCT06638931 · CT.gov ↗
What to watch
Phase 2Cancer of RectumRecruiting
Est. primary completion 2027-07 · NCT05732389 · CT.gov ↗
What to watch
Phase 2Basal Cell CarcinomaRecruiting
Est. primary completion 2027-07 · NCT03521830 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07 · NCT07084610 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-07-15 · NCT05111574 · CT.gov ↗
What to watch
Phase 2Carcinomas, Renal Medullary CarcinomaActive not recruiting
Est. primary completion 2027-07-16 · NCT05347212 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-07-30 · NCT02496208 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2027-07-30 · NCT07149090 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-07-31 · NCT02845323 · CT.gov ↗
What to watch
August 2027 (14)
Phase 1MelanomaActive not recruiting
Est. primary completion 2027-08 · NCT06377111 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or PembrolizumabRecruiting
Est. primary completion 2027-08 · NCT05901285 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-08 · NCT03635892 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-08 · NCT05663775 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-08 · NCT03576417 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07075120 · CT.gov ↗
What to watch
Phase 1Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid NeoplasmActive not recruiting
Est. primary completion 2027-08-01 · NCT03502733 · CT.gov ↗
What to watch
Phase 1Primary Diffuse Large B-Cell Lymphoma of the Central Nervous SystemActive not recruiting
Est. primary completion 2027-08-01 · NCT04609046 · CT.gov ↗
What to watch
Phase 2Neoplasms, Carcinoma, Squamous, Antineoplastic AgentsRecruiting
Est. primary completion 2027-08-01 · NCT05964101 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2027-08-02 · NCT05896839 · CT.gov ↗
What to watch
Phase 2Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma …Recruiting
Est. primary completion 2027-08-03 · NCT04745949 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2027-08-16 · NCT07476326 · CT.gov ↗
What to watch
Phase 3Extensive-Stage Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-17 · NCT06646276 · CT.gov ↗
What to watch
Phase 2Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter SyndromeActive not recruiting
Est. primary completion 2027-08-24 · NCT05672173 · CT.gov ↗
What to watch
September 2027 (12)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-09 · NCT07152678 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-09 · NCT06253611 · CT.gov ↗
What to watch
Phase 2Advanced or Metastatic Gastrooesophageal CarcinomaRecruiting
Est. primary completion 2027-09 · NCT07213557 · CT.gov ↗
What to watch
Phase 2SARCOMAActive not recruiting
Est. primary completion 2027-09 · NCT03282344 · CT.gov ↗
What to watch
Phase 2Endometrial Adenocarcinoma, Endometrial CarcinosarcomaActive not recruiting
Est. primary completion 2027-09 · NCT04106414 · CT.gov ↗
What to watch
Phase 3MelanomaActive not recruiting
Est. primary completion 2027-09 · NCT04309409 · CT.gov ↗
What to watch
Phase 2Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma …Active not recruiting
Est. primary completion 2027-09-01 · NCT02978625 · CT.gov ↗
What to watch
Phase 1Metastatic Pancreatic CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT06532331 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2027-09-30 · NCT04697576 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT04884282 · CT.gov ↗
What to watch
Phase 2Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic SyndromeActive not recruiting
Est. primary completion 2027-09-30 · NCT02530463 · CT.gov ↗
What to watch
October 2027 (14)
Phase 2Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H TumorsActive not recruiting
Est. primary completion 2027-10 · NCT03607890 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT05361720 · CT.gov ↗
What to watch
Phase 3Solid Tumor MalignanciesRecruiting
Est. primary completion 2027-10-01 · NCT07174453 · CT.gov ↗
What to watch
Phase 2Relapsed Classic Hodgkin LymphomaRecruiting
Est. primary completion 2027-10-02 · NCT04561206 · CT.gov ↗
What to watch
Phase 1Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma …Active not recruiting
Est. primary completion 2027-10-07 · NCT03884998 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsActive not recruiting
Est. primary completion 2027-10-14 · NCT06544655 · CT.gov ↗
What to watch
Phase 1Advanced Malignant TumorsRecruiting
Est. primary completion 2027-10-15 · NCT06764771 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-15 · NCT05012254 · CT.gov ↗
What to watch
Phase 3MelanomaRecruiting
Est. primary completion 2027-10-16 · NCT06112314 · CT.gov ↗
What to watch
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-10-30 · NCT05663710 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-10-31 · NCT07376707 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-10-31 · NCT06547385 · CT.gov ↗
What to watch
Phase 2Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma …Active not recruiting
Est. primary completion 2027-10-31 · NCT03307616 · CT.gov ↗
What to watch
Phase 2/3Gastric CancerRecruiting
Est. primary completion 2027-10-31 · NCT06203600 · CT.gov ↗
What to watch
November 2027 (8)
Phase 1Malignant Pleural MesotheliomaActive not recruiting
Est. primary completion 2027-11 · NCT04162015 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-11 · NCT06132945 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11 · NCT06901817 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-11 · NCT03406247 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT05098210 · CT.gov ↗
What to watch
Phase 1Phase 1b, HC-7366, SHARK, Kidney CancerRecruiting
Est. primary completion 2027-11-30 · NCT07401875 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-11-30 · NCT03838159 · CT.gov ↗
What to watch
Phase 2Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaRecruiting
Est. primary completion 2027-11-30 · NCT05039073 · CT.gov ↗
What to watch
December 2027 (25)
Phase 2Hodgkin Lymphoma, Hodgkin Disease, Advanced Hodgkin LymphomaRecruiting
Est. primary completion 2027-12 · NCT07209059 · CT.gov ↗
What to watch
Phase 2Esophageal Adenocarcinoma, Gastric AdenocarcinomaRecruiting
Est. primary completion 2027-12 · NCT04150640 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-12 · NCT07230613 · CT.gov ↗
What to watch
Early phase / not applicableMelanomaRecruiting
Est. primary completion 2027-12 · NCT07364474 · CT.gov ↗
What to watch
Phase 1Cervical CarcinomaRecruiting
Est. primary completion 2027-12-01 · NCT07653503 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-08 · NCT02910700 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-12-30 · NCT04017650 · CT.gov ↗
What to watch
Phase 2BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma …Active not recruiting
Est. primary completion 2027-12-30 · NCT04061980 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06540261 · CT.gov ↗
What to watch
Phase 1MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT04930783 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04013542 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2027-12-31 · NCT05655312 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04165330 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT06362369 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT02696993 · CT.gov ↗
What to watch
Phase 2Pan-tumorRecruiting
Est. primary completion 2027-12-31 · NCT04566380 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04729322 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT05048212 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06863311 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CancerRecruiting
Est. primary completion 2027-12-31 · NCT04875611 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
Phase 3Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-12-31 · NCT03233711 · CT.gov ↗
What to watch
Early phase / not applicableMelanomaRecruiting
Est. primary completion 2027-12-31 · NCT07564570 · CT.gov ↗
What to watch
2028 (61)
January 2028 (6)
Phase 2Hodgkin Lymphoma, AdultRecruiting
Est. primary completion 2028-01 · NCT06984146 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-01-01 · NCT05779423 · CT.gov ↗
What to watch
Phase 2Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IVActive not recruiting
Est. primary completion 2028-01-01 · NCT05788081 · CT.gov ↗
What to watch
Phase 3MelanomaActive not recruiting
Est. primary completion 2028-01-25 · NCT06054555 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2028-01-30 · NCT06163820 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2028-01-31 · NCT05504252 · CT.gov ↗
What to watch
February 2028 (4)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-02-15 · NCT06948448 · CT.gov ↗
What to watch
Phase 2MelanomaNot yet recruiting
Est. primary completion 2028-02-27 · NCT07862530 · CT.gov ↗
What to watch
Phase 1Solid Tumor, Locally Advanced Solid Tumor, Metastatic TumorRecruiting
Est. primary completion 2028-02-28 · NCT07404332 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2028-02-28 · NCT04380545 · CT.gov ↗
What to watch
March 2028 (9)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03 · NCT06800339 · CT.gov ↗
What to watch
Phase 1Advanced or Metastatic Solid TumorsActive not recruiting
Est. primary completion 2028-03 · NCT03155061 · CT.gov ↗
What to watch
Phase 1Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant …Enrolling by invitation
Est. primary completion 2028-03 · NCT06896110 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-03 · NCT06999980 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-03-01 · NCT05684276 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-03-17 · NCT05428007 · CT.gov ↗
What to watch
Phase 1Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease …Recruiting
Est. primary completion 2028-03-30 · NCT03816345 · CT.gov ↗
What to watch
Phase 2Gastric CancerEnrolling by invitation
Est. primary completion 2028-03-30 · NCT07542262 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2028-03-31 · NCT05423262 · CT.gov ↗
What to watch
April 2028 (4)
Phase 1Breast CancerRecruiting
Est. primary completion 2028-04 · NCT07319195 · CT.gov ↗
What to watch
Phase 4Renal Cell CarcinomaRecruiting
Est. primary completion 2028-04 · NCT06934057 · CT.gov ↗
What to watch
Phase 2Recurrent/ Metastatic Olfactory NeuroblastomaRecruiting
Est. primary completion 2028-04-14 · NCT07100704 · CT.gov ↗
What to watch
Phase 1/2Solid Tumor, AdultActive not recruiting
Est. primary completion 2028-04-30 · NCT04725474 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Basal Cell CarcinomaRecruiting
Est. primary completion 2028-05 · NCT06624475 · CT.gov ↗
What to watch
Phase 1CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade GliomasRecruiting
Est. primary completion 2028-05-01 · NCT07017816 · CT.gov ↗
What to watch
June 2028 (9)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-06 · NCT03767348 · CT.gov ↗
What to watch
Phase 2Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2028-06-01 · NCT03080974 · CT.gov ↗
What to watch
Phase 2Hepato Cellular Carcinoma (HCC), Renal Cell CancerNot yet recruiting
Est. primary completion 2028-06-01 · NCT07494435 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2028-06-06 · NCT06794229 · CT.gov ↗
What to watch
Phase 1Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Synovial Sarcoma, Soft Tissue Sarcoma …Recruiting
Est. primary completion 2028-06-30 · NCT04995003 · CT.gov ↗
What to watch
Phase 1Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III GliomaActive not recruiting
Est. primary completion 2028-06-30 · NCT04323046 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT05317000 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-06-30 · NCT03110978 · CT.gov ↗
What to watch
Phase 2Down Syndrome, Recurrent B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-06-30 · NCT04546399 · CT.gov ↗
What to watch
July 2028 (6)
Phase 4Oncology, Infusion ReactionRecruiting
Est. primary completion 2028-07 · NCT06031233 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaEnrolling by invitation
Est. primary completion 2028-07-01 · NCT06204614 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-07-30 · NCT05909618 · CT.gov ↗
What to watch
Phase 1Gastric CancerRecruiting
Est. primary completion 2028-07-31 · NCT05187182 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2028-07-31 · NCT07631325 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-07-31 · NCT05704647 · CT.gov ↗
What to watch
August 2028 (3)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-08-15 · NCT07420439 · CT.gov ↗
What to watch
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaRecruiting
Est. primary completion 2028-08-25 · NCT07128680 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Oral Squamous Cell Carcinoma (OSCC)Not yet recruiting
Est. primary completion 2028-09 · NCT07514767 · CT.gov ↗
What to watch
Phase 2Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor, Neoadjuvant TherapyNot yet recruiting
Est. primary completion 2028-09-02 · NCT07902258 · CT.gov ↗
What to watch
October 2028 (3)
Phase 4Renal Cell CarcinomaRecruiting
Est. primary completion 2028-10 · NCT07028125 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-10-01 · NCT06284564 · CT.gov ↗
What to watch
Early phase / not applicableRenal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT07233668 · CT.gov ↗
What to watch
November 2028 (6)
Phase 2Locally Advanced Solid TumorRecruiting
Est. primary completion 2028-11 · NCT06534190 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-11 · NCT06295159 · CT.gov ↗
What to watch
Phase 1/2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-11-01 · NCT05501054 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-11-01 · NCT06053658 · CT.gov ↗
What to watch
Early phase / not applicableMelanomaRecruiting
Est. primary completion 2028-11-05 · NCT04605146 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2028-11-08 · NCT05677490 · CT.gov ↗
What to watch
December 2028 (7)
Phase 1/2Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, CancerRecruiting
Est. primary completion 2028-12 · NCT03686124 · CT.gov ↗
What to watch
Phase 1/2Low Grade Glioma, High Grade GliomaRecruiting
Est. primary completion 2028-12 · NCT06712875 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2028-12 · NCT06941857 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-12 · NCT07527858 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal CancerRecruiting
Est. primary completion 2028-12 · NCT07645118 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-12-15 · NCT06708949 · CT.gov ↗
What to watch
Phase 1B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome …Recruiting
Est. primary completion 2028-12-31 · NCT03017820 · CT.gov ↗
What to watch
2029 (40)
January 2029 (3)
Phase 1/2HIV I InfectionRecruiting
Est. primary completion 2029-01 · NCT05187429 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2029-01-04 · NCT06697197 · CT.gov ↗
What to watch
Phase 2Rhabdoid TumorRecruiting
Est. primary completion 2029-01-31 · NCT06622941 · CT.gov ↗
What to watch
February 2029 (2)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-02 · NCT06823479 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2029-02-28 · NCT05629546 · CT.gov ↗
What to watch
March 2029 (4)
Phase 2MelanomaRecruiting
Est. primary completion 2029-03 · NCT07740941 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-03-01 · NCT04248569 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-03-17 · NCT06495125 · CT.gov ↗
What to watch
Phase 2/3Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaNot yet recruiting
Est. primary completion 2029-03-31 · NCT07572123 · CT.gov ↗
What to watch
April 2029 (4)
Phase 1Urothelial CarcinomaRecruiting
Est. primary completion 2029-04 · NCT07532902 · CT.gov ↗
What to watch
Phase 3Primary Mediastinal LymphomaActive not recruiting
Est. primary completion 2029-04-01 · NCT06188676 · CT.gov ↗
What to watch
Phase 2Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8Recruiting
Est. primary completion 2029-04-30 · NCT06029270 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-04-30 · NCT06632327 · CT.gov ↗
What to watch
May 2029 (4)
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2029-05 · NCT06812858 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2029-05 · NCT07504796 · CT.gov ↗
What to watch
Phase 2Adenocarcinoma of the Esophagogastric Junction, Perioperative PeriodActive not recruiting
Est. primary completion 2029-05-01 · NCT06681298 · CT.gov ↗
What to watch
Phase 4MelanomaNot yet recruiting
Est. primary completion 2029-05-26 · NCT07459543 · CT.gov ↗
What to watch
June 2029 (3)
Phase 1MelanomaRecruiting
Est. primary completion 2029-06-01 · NCT07501117 · CT.gov ↗
What to watch
Phase 2Newly Diagnosed GlioblastomaRecruiting
Est. primary completion 2029-06-01 · NCT06816927 · CT.gov ↗
What to watch
Phase 2Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder, Disorders, LymphoproliferativeRecruiting
Est. primary completion 2029-06-01 · NCT03258567 · CT.gov ↗
What to watch
July 2029 (4)
Phase 1/2MelanomaRecruiting
Est. primary completion 2029-07 · NCT06240143 · CT.gov ↗
What to watch
Phase 2Anaplastic Large Cell Lymphoma, ALK-PositiveRecruiting
Est. primary completion 2029-07-01 · NCT07013565 · CT.gov ↗
What to watch
Phase 2Richter's TransformationRecruiting
Est. primary completion 2029-07-31 · NCT06936943 · CT.gov ↗
What to watch
Phase 4Solid TumorsRecruiting
Est. primary completion 2029-07-31 · NCT05203172 · CT.gov ↗
What to watch
August 2029 (5)
Phase 2Breast Cancer, Leptomeningeal DiseaseRecruiting
Est. primary completion 2029-08 · NCT07694986 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2029-08-16 · NCT07431281 · CT.gov ↗
What to watch
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-08-31 · NCT07576725 · CT.gov ↗
What to watch
September 2029 (6)
Phase 1/2Vulvar Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-09 · NCT07679841 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09 · NCT07563738 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-09 · NCT07219459 · CT.gov ↗
What to watch
Phase 1/2Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children, NivolumabEnrolling by invitation
Est. primary completion 2029-09-01 · NCT06871007 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2029-09-04 · NCT07818018 · CT.gov ↗
What to watch
Phase 2HIV-1Recruiting
Est. primary completion 2029-09-15 · NCT07820813 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2029-10 · NCT07234487 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-10-01 · NCT07246863 · CT.gov ↗
What to watch
November 2029 (2)
Phase 1MelanomaNot yet recruiting
Est. primary completion 2029-11-01 · NCT07838974 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-11-02 · NCT04665206 · CT.gov ↗
What to watch
December 2029 (1)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07902921 · CT.gov ↗
What to watch
2030 (34)
January 2030 (4)
Phase 2HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric AdenocarcinomaActive not recruiting
Est. primary completion 2030-01 · NCT07546812 · CT.gov ↗
What to watch
Phase 2/3MelanomaRecruiting
Est. primary completion 2030-01 · NCT06581406 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01-31 · NCT07718243 · CT.gov ↗
What to watch
Phase 3Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 …Active not recruiting
Est. primary completion 2030-01-31 · NCT03811015 · CT.gov ↗
What to watch
March 2030 (3)
Phase 2Gastric CancerRecruiting
Est. primary completion 2030-03 · NCT07432295 · CT.gov ↗
What to watch
Phase 1Brain Cancer, HGG, Glioma, High Grade Glioma, High Grade Gliomas, High Grade Glioma (III or IV) …Recruiting
Est. primary completion 2030-03-30 · NCT07210632 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-03-31 · NCT06926790 · CT.gov ↗
What to watch
April 2030 (2)
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2030-04 · NCT07460765 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-04-01 · NCT04564157 · CT.gov ↗
What to watch
May 2030 (1)
Phase 3Renal Cell CarcinomaEnrolling by invitation
Est. primary completion 2030-05-31 · NCT07620574 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1Neuroendocrine Carcinoma, Neuroendocrine TumorsRecruiting
Est. primary completion 2030-06-01 · NCT06889493 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-30 · NCT06561386 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1/2MelanomaRecruiting
Est. primary completion 2030-08-16 · NCT06683755 · CT.gov ↗
What to watch
September 2030 (4)
Phase 3MelanomaRecruiting
Est. primary completion 2030-09 · NCT06488482 · CT.gov ↗
What to watch
Phase 2/3Urothelial CarcinomaRecruiting
Est. primary completion 2030-09-02 · NCT05987241 · CT.gov ↗
What to watch
Phase 4Renal Cell CarcinomaRecruiting
Est. primary completion 2030-09-24 · NCT07872553 · CT.gov ↗
What to watch
Phase 3MelanomaRecruiting
Est. primary completion 2030-09-30 · NCT06264180 · CT.gov ↗
What to watch
October 2030 (4)
Phase 1Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)Recruiting
Est. primary completion 2030-10 · NCT07090148 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-10 · NCT07430202 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2030-10-18 · NCT07848295 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2030-10-21 · NCT07930182 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-30 · NCT07223424 · CT.gov ↗
What to watch
December 2030 (12)
Phase 1Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas, Medulloblastoma Recurrent, Ependymoma Recurrent …Recruiting
Est. primary completion 2030-12 · NCT07664176 · CT.gov ↗
What to watch
Phase 1Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma, Ependymoma, Grade IV AstrocytomaActive not recruiting
Est. primary completion 2030-12 · NCT07031765 · CT.gov ↗
What to watch
Phase 1/2Metastatic Triple-negative Breast CancerRecruiting
Est. primary completion 2030-12 · NCT06963905 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2030-12 · NCT07281924 · CT.gov ↗
What to watch
Phase 1Metastatic Colorectal CancerRecruiting
Est. primary completion 2030-12-02 · NCT07328087 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-12-12 · NCT04929041 · CT.gov ↗
What to watch
Phase 2Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-12-15 · NCT04159818 · CT.gov ↗
What to watch
Phase 1/2Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue SarcomaRecruiting
Est. primary completion 2030-12-31 · NCT03138161 · CT.gov ↗
What to watch
Phase 2SarcomaRecruiting
Est. primary completion 2030-12-31 · NCT03886311 · CT.gov ↗
What to watch
Phase 2LOCALLY ADVANCED CERVICAL CANCERSActive not recruiting
Est. primary completion 2030-12-31 · NCT06715241 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2030-12-31 · NCT07551583 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-12-31 · NCT07050043 · CT.gov ↗
What to watch
2031 (13)
January 2031 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2031-01-01 · NCT03815890 · CT.gov ↗
What to watch
February 2031 (2)
Phase 1/2Pediatric CancerRecruiting
Est. primary completion 2031-02 · NCT02813135 · CT.gov ↗
What to watch
Phase 1/2Lung Cancer, Breast CancerRecruiting
Est. primary completion 2031-02-26 · NCT06618287 · CT.gov ↗
What to watch
April 2031 (2)
Phase 2Locally Advanced Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2031-04 · NCT04910347 · CT.gov ↗
What to watch
Phase 3Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8Recruiting
Est. primary completion 2031-04-28 · NCT05675410 · CT.gov ↗
What to watch
August 2031 (3)
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2031-08-01 · NCT06866262 · CT.gov ↗
What to watch
Phase 2Malignant Neoplasms of Digestive OrgansRecruiting
Est. primary completion 2031-08-06 · NCT05934331 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-08-31 · NCT04895709 · CT.gov ↗
What to watch
September 2031 (2)
Phase 2AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2031-09-15 · NCT04929028 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2031-09-30 · NCT07741565 · CT.gov ↗
What to watch
October 2031 (1)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2031-10-31 · NCT07689175 · CT.gov ↗
What to watch
December 2031 (2)
Phase 3Advanced Kidney CancerNot yet recruiting
Est. primary completion 2031-12 · NCT07338981 · CT.gov ↗
What to watch
Phase 1Soft Tissue SarcomasRecruiting
Est. primary completion 2031-12-31 · NCT07444619 · CT.gov ↗
What to watch
2032 (9)
January 2032 (1)
Phase 2Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 …Recruiting
Est. primary completion 2032-01-03 · NCT06745076 · CT.gov ↗
What to watch
February 2032 (1)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2032-02-18 · NCT05533697 · CT.gov ↗
What to watch
March 2032 (1)
Phase 2Colon CarcinomaRecruiting
Est. primary completion 2032-03-01 · NCT03026140 · CT.gov ↗
What to watch
April 2032 (2)
Phase 3MelanomaRecruiting
Est. primary completion 2032-04-15 · NCT06794775 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-04-30 · NCT04114136 · CT.gov ↗
What to watch
May 2032 (2)
Phase 2Limited Stage Small Cell Lung CancerActive not recruiting
Est. primary completion 2032-05 · NCT06773910 · CT.gov ↗
What to watch
Phase 3Metastatic Kidney Cancer, Metastatic Kidney CarcinomaRecruiting
Est. primary completion 2032-05-05 · NCT06364631 · CT.gov ↗
What to watch
July 2032 (2)
Phase 2Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma …Recruiting
Est. primary completion 2032-07-30 · NCT05112601 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-07-31 · NCT07355205 · CT.gov ↗
What to watch
2033 (3)
March 2033 (1)
Phase 2High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Replication Repair DeficientNot yet recruiting
Est. primary completion 2033-03-01 · NCT07644312 · CT.gov ↗
What to watch
June 2033 (1)
Phase 2/3MelanomaActive not recruiting
Est. primary completion 2033-06-30 · NCT02339571 · CT.gov ↗
What to watch
August 2033 (1)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2033-08-01 · NCT07510334 · CT.gov ↗
What to watch
2034 (1)
April 2034 (1)
Phase 3Von Hippel-Lindau Disease, Malignant NeoplasmsRecruiting
Est. primary completion 2034-04-22 · NCT07405164 · CT.gov ↗
What to watch
2040 (1)
February 2040 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2040-02-28 · NCT07770100 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 March 2024Topline resultCheckMate -9DW (NCT04039607) Phase 3 met its primary endpoint
Bristol Myers Squibb · Source ↗